Oral GLP-1 Drugs Curb Pleasure Eating by Dampening a Brain Reward Signal

Overview

• NIH-funded University of Virginia researchers reported in Nature that oral small‑molecule GLP‑1 drugs changed reward processing in mice.
• The team used orforglipron and danuglipron in mice engineered with humanlike GLP‑1 receptors to track where the drugs act in the brain.
• The drugs activated neurons in the central amygdala and cut dopamine release in key reward hubs during hedonic, or pleasure‑driven, feeding.
• The results suggest these pills reach deeper brain regions than many expected and act through a pathway distinct from classic hunger circuits.
• Authors say the mechanism could clarify why some drugs cause more nausea while others blunt food desire, and they plan tests on non‑food cravings such as substance use, which remain unproven in people.